GeneDx is trading 12.7% down at $58.62 on October 23, 2026, with biotech-sector weakness offering context but no confirmed company-specific cause.
- The XBI was down 2.08% during the regular session; sector weakness may have contributed but does not establish the reason for GeneDx’s larger drop.
- An October 23 report described long-read sequencing plans and accepted scientific abstracts, not a negative catalyst for the day’s move.